Suscribirse

Risk stratification for advanced proximal colon neoplasm and individualized endoscopic screening for colorectal cancer by a risk-scoring model - 17/09/12

Doi : 10.1016/j.gie.2012.06.013 
Hye Won Park, MD 1, Seungbong Han, PhD 2, Jong-Soo Lee, MD 1, Hye-Sook Chang, MD 1, Don Lee, MD 1, Jae-Won Choe, MD 1, Seung-Jae Myung, MD 3, Suk-Kyun Yang, MD 3, Jin-Ho Kim, MD 3, Jeong-Sik Byeon, MD 3,
1 Health Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 
2 Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 
3 Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 

Reprint requests: Jeong-Sik Byeon, Department of Gastroenterology, Asan Medical Center, 86, Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Korea

Resumen

Background

Only 30% to 40% of patients with advanced proximal neoplasms (APN) have distal colon neoplasms.

Objective

To develop a risk score model for APN and propose an individualized screening protocol for colorectal cancer.

Design

Retrospective cohort study.

Setting

Tertiary-care center.

Patients

Derivation cohort (6200 adults) and validation cohort (1389 adults).

Intervention

Screening colonoscopy.

Main Outcome Measurements

An APN risk score model was developed from the derivation cohort (6200 adults) and was tested in the validation cohort (1389 adults), who underwent screening colonoscopy.

Results

Age, male sex, and smoking were clinical risk factors for APN. The presence of a distal neoplasm was a sigmoidoscopic risk factor for APN. We calculated APN risk scores (0-8) based on these variables and classified patients as low risk (0-2) or high risk (3-8). In the validation cohort, the relative risk of APN was 3.5-fold higher in the high-risk group than in the low-risk group. Our model suggests that colonoscopy should be performed as an initial screening test in patients with a high clinical risk for APN. Sigmoidoscopy should be performed initially in patients with low clinical risk for APN followed by supplementary colonoscopy in those with high APN risk scores based on both clinical and sigmoidoscopic risk factors. This protocol detected APN in 22 of 34 APN+ patients (64.7%) with little increase in the endoscopy burden, whereas only 16 of 34 APN+ patients (47.1%) would be identified by initial sigmoidoscopy followed by colonoscopy only in cases with distal neoplasms.

Limitations

Retrospective design.

Conclusion

Our APN risk score model provides an algorithm for efficient screening of colorectal cancer by sigmoidoscopy and colonoscopy.

El texto completo de este artículo está disponible en PDF.

Abbreviations : ADN, APN, score-C, score-CS, FS


Esquema


 DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.
 See CME section; p. 835.


© 2012  American Society for Gastrointestinal Endoscopy. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 76 - N° 4

P. 818-828 - octobre 2012 Regresar al número
Artículo precedente Artículo precedente
  • Water immersion simplifies cecal intubation in patients with redundant colons and previous incomplete colonoscopies
  • Krishna C. Vemulapalli, Douglas K. Rex
| Artículo siguiente Artículo siguiente
  • Submucosal endoscopy with mucosal resection: a hybrid endoscopic submucosal dissection in the porcine rectum and distal colon
  • Christopher J. Gostout, Mary A. Knipschield

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.